. . . . . . . "Humans and other mammals"@en . "BIBW 2992"@en . . . . "When given with a high-fat meal, Cmax decreases by 50% and AUC by 39% relative to the fasted state. "@en . . . . . "850140-72-6"@en . . . "Afatinib is an irreversible kinase inhibitor and binds to the kinase domains of EGFR (ErbB1), HER2 (ErbB2), and HER4 (ErbB4) to inhibit tyrosine kinase autophosphorylation. This results in a downregulation of ErbB signalling and subsequent inhibition of proliferation of cell lines expressing wild-type EGFR, selected EGFR exon 19 deletion mutations, or exon 21 L858R mutations. It also inhibited in vitro proliferation of cell lines overexpressing HER2. Overall, tumour growth was inhibited. "@en . . "Afatinib is a kinase inhibitor indicated for the first-line treatment of patient with metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test."@en . "Excretion of afatinib is primarily via the feces (85%), with 4% recovered in the urine following a single oral dose of afatinib solution. The parent compound accounted for 88% of the recovered dose. "@en . . . . . " "@en . . "Afatinibum"@en . . . "Afatinib is a tyrosine kinase inhibitor which is a 4-anilinoquinazoline. It is prepared has the dimaleate salt. FDA approved on July 12, 2013. "@en . . . . . . "Following oral administration, time to peak plasma concentration (Tmax) is 2 to 5 hours. The geometric mean relative bioavailability of 20 mg tablets was 92% as compared to an oral solution. Food decreases Cmax and AUC relative to the fasted state. "@en . . . "Cancer patients, repeat dosing = 37 hours "@en . . . "# FDA label "@en . "Most common adverse reactions (\u226520%) are diarrhea, rash/dermatitis, acneiform, stomatitis, paronychia, dry skin, decreased appetite, pruritus. "@en . "95% bound to human plasma protein. "@en . . "approved"@en . . . . "Afatinib"@en . . . . .